Why LUMIGAN® 0.01% (bimatoprost ophthalmic solution)?

- LUMIGAN® 0.01% is an FDA-approved medication to lower the pressure inside the eyes (intraocular pressure, or IOP)
- LUMIGAN® 0.01% has been proven to effectively lower the pressure inside the eyes (IOP)\(^1\)
- Your LUMIGAN® 0.01% prescription bottle will look slightly different

Insurance coverage with LUMIGAN® 0.01%

- LUMIGAN® 0.01% is covered by most insurance plans\(^2\)
- Your coverage will most likely not change from LUMIGAN® 0.03%

LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) is used for the treatment of high eye pressure, also called intraocular pressure (IOP), in people with open-angle glaucoma or ocular hypertension.

Important Safety Information

LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) has been reported to cause darkening (pigmentation) of eye color, eyelid skin, and eyelashes as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® 0.01% and 0.03% is used. After stopping LUMIGAN® 0.01% and 0.03%, darkening of eye color is likely to be permanent, while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond 5 years are not known.

Please see additional Important Safety Information on reverse side.

Make sure you receive LUMIGAN® 0.01% at the pharmacy, just as your doctor prescribed.
Daily treatment with LUMIGAN® 0.01% is critical

Remember to take your medication as prescribed

- LUMIGAN® 0.01% ophthalmic solution may work only when you use it as prescribed by your doctor
- Commit to taking your LUMIGAN® 0.01% therapy every day to help lower your IOP and help reduce the risk of vision loss

Useful tips to help you remember your LUMIGAN® 0.01% eyedrops

If you need help remembering your daily dose, try following these helpful suggestions:

- Associate using your eyedrops with other daily routines you’ve established for yourself, such as brushing your teeth
- Set a daily clock or watch alarm that can remind you to use your eyedrops
- Ask a friend or family member to remind you when it’s time to use your eyedrops

Important Safety Information (continued)

When only one eye is treated, there is a possibility of eyelash changes in the eye treated with LUMIGAN® 0.01% and 0.03%. These changes may result in differences between the eyes in eyelash length, thickness, darkness, number of eyelashes, and/or direction of eyelash growth. These changes are usually reversible upon stopping LUMIGAN® 0.01% and 0.03% therapy.

Avoid allowing the tip of the dispensing bottle to touch the eye, anything around the eye, fingers, or any other surface in order to avoid contamination by common bacteria known to cause eye infections. Serious damage to the eye and loss of vision may result from using contaminated solutions.

If you have eye surgery or develop any eye reactions (such as trauma or infection), immediately consult with your physician about continuing the use of LUMIGAN® 0.01% and 0.03%.

If you wear contact lenses, remove them before using LUMIGAN® 0.01% and 0.03%. Then wait 15 minutes after using LUMIGAN® 0.01% and 0.03% before you put your contacts back into your eyes.

The most common side effects are eye redness, growth of eyelashes, and itchy eyes.

Please see the accompanying full Prescribing Information, which is also available from your doctor.

Visit us at www.lumigan.com for more information and a money-saving offer.

1. LUMIGAN® 0.01% and 0.03% Prescribing Information.
2. Formulary Compass Database™, a trademark of MMIT, as of October 2011.
These highlights do not include all the information needed to use LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) safely and effectively. See full prescribing information for LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution).

**INDICATIONS AND USAGE**

LUMIGAN® is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. (1)

**CONTRAINDICATIONS**

Not for use in eyes with known hypersensitivity to the prostaglandin analogs or any component of the formulation.

**WARNINGS AND PRECAUTIONS**

- Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. (5.1)
- Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2)

**ADVERSE REACTIONS**

Most common adverse reaction (range 25%–45%) is conjunctival hyperemia. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**USE IN SPECIFIC POPULATIONS**

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

**FULL PRESCRIBING INFORMATION: CONTENTS**

1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
7 USE IN SPECIFIC POPULATIONS
8 USE IN PREGNANT WOMEN
9 USE IN NURSING MOTHERS
10 DOSAGE FORMS AND STRENGTHS
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
15 HOW SUPPLIED/STORAGE AND HANDLING
16 PATIENT COUNSELING INFORMATION
17 PATIENT COUNSELING INFORMATION
18 PACKAGE INSERT

**FULL PRESCRIBING INFORMATION**

1 INDICATIONS AND USAGE

LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. (5.1)

2 DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. (2)

LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.

LUMIGAN® may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

3 DOSAGE FORMS AND STRENGTHS

Ophthalmic solution containing bimatoprost 0.1 mg/mL (LUMIGAN® 0.01%) or containing bimatoprost 0.3 mg/mL (LUMIGAN® 0.03%).

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Pigmentation

Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periocular tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither new nor freckles of the iris appear to be affected by treatment. While treatment with LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly (see Patient Counseling Information). (17.1)

5.2 Eyelash Changes

LUMIGAN® 0.01% and 0.03% may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

5.3 Intraocular Inflammation

LUMIGAN® 0.01% and 0.03% should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

5.4 Macular Edema

LUMIGAN® 0.01% and 0.03% may gradually change eyelashes and vellus hair in the treated eye. Including ciliary macular edema, has been reported during treatment with bimatoprost ophthalmic solution. LUMIGAN® 0.01% and 0.03% should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

5.5 Angle-closure, Inflammatory, or Neovascular Glaucoma

LUMIGAN® 0.01% and 0.03% has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma.

5.6 Bacterial Keratitis

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface (see Patient Counseling Information).

5.7 Use with Contact Lenses

Contact lenses should be removed prior to instillation of LUMIGAN® 0.01% and 0.03% and may be reinserted 15 minutes following its administration.

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. In clinical studies with bimatoprost ophthalmic solutions (0.01% or 0.03%) the most common adverse reaction was conjunctival hyperemia (range 25%–45%). Approximately 0.5% to 3% of patients discontinued therapy due to conjunctival hyperemia with 0.01% or 0.03% bimatoprost ophthalmic solutions. Other common reactions (>10%) included growth of eyelashes, and ocular pruritus.

Additional ocular adverse reactions (reported in 1 to 10% of patients) with bimatoprost ophthalmic solutions included ocular dryness, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the pericorneal skin, blepharitis, cataract, superficial...
12.3 Pharmacokinetics

Absorption: After one drop of bimatoprost ophthalmic solution 0.03% was administered once daily to both eyes of 15 healthy subjects for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (0.025 ng/mL) in most subjects within 1.5 hours after dosing. Mean C_{max} and AUC_{0-24hr} values were similar on days 7 and 14 at approximately 0.08 ng/mL and 0.09 ng•hr/mL, respectively, indicating that steady state was reached during the first week of ocular dosing. There was no significant systemic drug accumulation over time.

Distribution: Bimatoprost is moderately distributed into body tissues with a steady-state volume of distribution of 0.67 L/kg. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma.

Metabolism: Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites.

Elimination: Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and disappeared rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage at doses of up to 2 mg/kg/day and 1 mg/kg/day respectively (at least 192 and 291 times the recommended human exposure based on blood AUC levels respectively) for 104 weeks.

Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus test. Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (at least 103 times the recommended human exposure based on blood AUC levels).

14 CLINICAL STUDIES

In clinical studies of patients with open angle glaucoma or ocular hypertension with a mean baseline IOP of 26 mmHg, the IOP-lowering effect of LUMIGAN® 0.03% (bimatoprost ophthalmic solution) once daily (in the evening) was 7.8 mmHg.

In a 3 month clinical study of patients with open angle glaucoma or ocular hypertension with an average baseline IOP of 23.5 mmHg, the IOP-lowering effect of LUMIGAN® 0.01% once daily (in the evening) was up to 7.5 mmHg and was approximately 0.5 mmHg less effective than LUMIGAN® 0.03%. In this same study, LUMIGAN® 0.01% also had a similar overall safety profile compared with LUMIGAN® 0.03%. After 12 months of treatment, discontinuations were 8.1% for LUMIGAN® 0.01% and 13.4% for LUMIGAN® 0.03%.

16 HOW SUPPLIED/STORAGE AND HANDLING

LUMIGAN® (bimatoprost ophthalmic solution) 0.01% is supplied sterile in opaque white low density polyethylene ophthalmic dispenser bottles and tips with turquoise polyvinyl capes in the following sizes:

- 2.5 mL fill in a 5 mL container - NDC 0023-3205-03
- 5 mL fill in a 10 mL container - NDC 0023-3205-05
- 7.5 mL fill in a 10 mL container - NDC 0023-3205-08

LUMIGAN® (bimatoprost ophthalmic solution) 0.03% is supplied sterile in opaque white low density polyethylene ophthalmic dispenser bottles and tips with turquoise polyvinyl capes in the following sizes:

- 2.5 mL fill in 5 mL container - NDC 0023-9187-03
- 5 mL fill in 10 mL container - NDC 0023-9187-05
- 7.5 mL fill in 10 mL container - NDC 0023-9187-07

Storage: LUMIGAN® 0.01% and 0.03% should be stored at 2°C to 25°C (36°F to 77°F).

17 PATIENT COUNSELING INFORMATION

17.1 Potential for Pigmentation

Patients should be advised about the potential for increased brown pigmentation of the iris, which may be permanent. Patients should also be informed about the possibility of eyelash skin darkening, which may be reversible after discontinuation of LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution).

17.2 Potential for Eyelash Changes

Patients should also be informed of the possibility of eyelash and vellus hair changes in the treated eye during treatment with LUMIGAN® 0.01% and 0.03%. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment.

17.3 Handling the Container

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

17.4 When to Seek Physician Advice

Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of LUMIGAN® 0.01% and 0.03%.

17.5 Use with Contact Lenses

Patients should be advised that LUMIGAN® 0.01% and 0.03% contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of LUMIGAN® and may be reinserted 15 minutes following its administration.

17.6 Use with Other Ophthalmic Drugs

Patients should be advised that if more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 (minutes) between applications.